[go: up one dir, main page]

EA201992594A1 - Комбинированные терапии для лечения рака - Google Patents

Комбинированные терапии для лечения рака

Info

Publication number
EA201992594A1
EA201992594A1 EA201992594A EA201992594A EA201992594A1 EA 201992594 A1 EA201992594 A1 EA 201992594A1 EA 201992594 A EA201992594 A EA 201992594A EA 201992594 A EA201992594 A EA 201992594A EA 201992594 A1 EA201992594 A1 EA 201992594A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
treatment
combined therapies
agent
signaling pathway
Prior art date
Application number
EA201992594A
Other languages
English (en)
Inventor
Дмитри Бобилев
Брюс Дезьюб
Пэн Сунь
Эндрю Р. Фергюсон
Original Assignee
Тесаро, Инк.
Мерк Шарп и Доум Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тесаро, Инк., Мерк Шарп и Доум Б.В. filed Critical Тесаро, Инк.
Priority claimed from PCT/US2018/031876 external-priority patent/WO2018208968A1/en
Publication of EA201992594A1 publication Critical patent/EA201992594A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предлагаются способы лечения рецидивирующего рака (рецидивирующих раков) путем применения комбинированной терапии, включающей средство, которое ингибирует активацию сигнального пути рецептора программируемой гибели клеток типа 1 (PD-1), и средство, которое ингибирует активацию сигнального пути поли[ADP-рибоза]полимеразы (PARP).
EA201992594A 2018-03-26 2018-05-09 Комбинированные терапии для лечения рака EA201992594A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648327P 2018-03-26 2018-03-26
PCT/US2018/031876 WO2018208968A1 (en) 2017-05-09 2018-05-09 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
EA201992594A1 true EA201992594A1 (ru) 2020-03-20

Family

ID=69942862

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992594A EA201992594A1 (ru) 2018-03-26 2018-05-09 Комбинированные терапии для лечения рака

Country Status (1)

Country Link
EA (1) EA201992594A1 (ru)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
US11661453B2 (en) 2017-09-30 2023-05-30 Tesaro, Inc. Combination therapies for treating cancer with niraparib and PD-1 inhibitors
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
US12156872B2 (en) 2017-05-09 2024-12-03 Tesaro, Inc. Combination therapies for treating cancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12156872B2 (en) 2017-05-09 2024-12-03 Tesaro, Inc. Combination therapies for treating cancer
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
US11661453B2 (en) 2017-09-30 2023-05-30 Tesaro, Inc. Combination therapies for treating cancer with niraparib and PD-1 inhibitors
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof

Similar Documents

Publication Publication Date Title
ZA201907395B (en) Combination therapies for treating cancer
MX2019013755A (es) Terapias de combinación para el tratamiento del cáncer.
EA201992594A1 (ru) Комбинированные терапии для лечения рака
PH12017501857B1 (en) Pd-l1 antagonist combination treatments
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
PH12022551486A1 (en) Compounds and methods for the targeted degradation of androgen receptor
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
PH12019502259A1 (en) Glucocorticoid receptor modulators to treat cervical cancer
NZ754865A (en) Combination therapy for the treatment of cancer
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
EA202191556A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
EA201892284A1 (ru) Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
ZA201907225B (en) Treatment of her2 positive cancers
AR116121A1 (es) Métodos de tratamiento del cáncer
MX2023003034A (es) Metodos, terapias y usos para tratar el cancer.
MX2018010847A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
MX2021008903A (es) Compuestos y usos de los mismos.
MX2020008408A (es) Imagenologia y terapia dirigidas por la granzima b.
MX2019011692A (es) Nuevo tratamiento de enfermedades mitocondriales.
MX2021003062A (es) Terapia combinada para tratar el cancer de sangre.